Mirum Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 15, 2024
MIRM$93.18-0.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $286,326 | $28,003 |
| Short-term investments | — | 123,716 |
| Accounts receivable | 67,968 | 23,994 |
| Inventory | 22,312 | 5,565 |
| Prepaid expenses and other current assets | 10,935 | 8,947 |
| Total current assets | 387,541 | 190,225 |
| Restricted cash equivalents | — | 100,000 |
| Property and equipment, net | 706 | 914 |
| Operating lease right-of-use assets | 1,284 | 1,431 |
| Intangible assets, net | 252,925 | 58,954 |
| Other assets | 4,165 | 1,382 |
| Total assets | $646,621 | $352,906 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $7,416 | $8,690 |
| Accrued expenses | 78,544 | 54,018 |
| Operating lease liabilities | 1,104 | 931 |
| Derivative liability | — | 1,090 |
| Total current liabilities | 87,064 | 64,729 |
| Revenue interest liability, net | — | 140,351 |
| Operating lease liabilities, noncurrent | 617 | 1,257 |
| Convertible notes payable, net | 306,421 | — |
| Other liabilities | 3,849 | 4,532 |
| Total liabilities | 397,951 | 210,869 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized, and no shares issued and outstanding as of December 31, 2023 and 2022; | — | — |
| Common stock, $0.0001 par value; 200,000,000 shares authorized; 46,723,143 and 36,956,345 shares issued and outstanding as of December 31, 2023 and 2022 | 5 | 4 |
| Additional paid-in capital | 803,260 | 535,074 |
| Accumulated deficit | (556,239) | (392,824) |
| Accumulated other comprehensive income (loss) | 1,644 | (217) |
| Total stockholders’ equity | 248,670 | 142,037 |
| Total liabilities and stockholders’ equity | $646,621 | $352,906 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.